PDCD1 and primary biliary cholangitis: In the EV-302 study, only 32.2% patients received a PD-1/L1 inhibitor as maintenance therapy after PBC, and only 20% patients in the GC arm of the CheckMate-901 study received a PD-1/L1 inhibitor before progression.